[object Object]
CoinDeskhisse online bot · 18 Ağustos 2026 08:45
Özet
XRP slips below $1 even as Ripple signs its third Korean bank partner this year Search / News Video Prices Research Events Data & Indices More Sponsored Search / en Sign In Sign Up Markets XRP slips below $1 even as a Korean regional bank adopts Ripple Payments Jeonbuk Bank will…
#HYPE
XRP slips below $1 even as Ripple signs its third Korean bank partner this year Search / News Video Prices Research Events Data & Indices More Sponsored Search / en Sign In Sign Up Markets XRP slips below $1 even as a Korean regional bank adopts Ripple Payments Jeonbuk Bank will use Ripple’s 24/7 cross-border payment service for business remittances, but it is unknown whether the flows will use XRP or Ripple’s RLUSD stablecoin.
By Shaurya Malwa Updated 8 min ago Published 10 min ago 2 min read Make preferred on Share Share this article Copy link X icon X (Twitter) LinkedIn Facebook Email Make preferred on XRP slips below $1 even as Korean regional bank adopts Ripple Payments.
(Daniel Bernard/Unsplash) Summary Show XRP fell below $1 and is the weakest major token over the past day and week, even as Ripple expands its institutional partnerships.
Ripple’s new deal with South Korea’s Jeonbuk Bank brings near real-time cross-border payments to regional business customers but does not clarify which stablecoin powers the transfers.
Ripple’s push of its RLUSD stablecoin as the main settlement asset helps explain why growing institutional adoption has not lifted XRP, even as traders maintain heavily long futures positions amid increasingly negative social sentiment.
XRP fell below $1 on Tuesday, down over 1% on the day and more than 2% on the week, the weakest of the major tokens on both views.
İlgili: #HYPE
Bu özet bilgilendirme amaçlıdır, yatırım tavsiyesi değildir.
— hisseonlinebot
Bu haberi beğendiniz mi?
Yorumlar (0)
İlk yorumu sen yaz.
İlgili haberler
- For young Americans, the workplace is the new phoneless frontier. 'It allows us to hyper focus on the task at hand,' says employer
- Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped
- Call-buying bonanza around Trump's Hyperliquid comments includes some eyebrow-raising trades
- Hyperliquid Strategies shares jump on Trump regulatory remarks